Creo Medical: Deutsche Bank Maintains 'Buy' Rating with 40p Target

Deutsche Bank maintains a "buy" rating on Creo Medical Group with a price target of 40p. The medtech firm reported 50% revenue growth in FY25, driven by increased adoption of core products and sustained demand. Deutsche remains confident in Creo's outlook for FY26 and beyond, with potential upside to current revenue forecasts. The shares continue to trade at a significant discount to Deutsche's discounted cash flow valuation, suggesting further room for recovery.